Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 31:13:1253845.
doi: 10.3389/fonc.2023.1253845. eCollection 2023.

Management pattern and medication-related harms and its predictors in colorectal cancer patients: an institutional-based retrospective study

Belayneh Kefale  1 , Melaku Tadege Engidaw  2 , Desalegn Tesfa  2 , Mulugeta Molla  3 , Yitayih Kefale  4 , Chernet Tafere  5
Affiliations

Management pattern and medication-related harms and its predictors in colorectal cancer patients: an institutional-based retrospective study

Belayneh Kefale et al. Front Oncol. .

Abstract

Introduction: Data on colorectal cancer (CRC) patients' thorough management practices and medication-related harms (MRH) are scarce. This study's aim was to investigate the MRHs in patients receiving CRC chemotherapy at the comprehensive specialized hospital of the University of Gondar (UoGCSH).

Methods: A registry-based retrospective cohort study was conducted on CRC patients at the UoGCSH during 2017-2021. From February to May 2022, medical records were reviewed using a pretested data collection tool to collect socio-demographic and disease-related characteristics, MRHs, and medication regimens. MRHs occurrence and adverse drug reactions (ADRs) severity were assessed using standard guidelines and protocols. Version 16/MP of STATA for Windows was used for the analysis. Independent predictors of MRHs were investigated using logistic regression analysis. A p-value ≤0.05 was used to determine an independent variable's statistical significance.

Results: One hundred forty three CRC patients were included, with a mean age of 49.9 ± 14.5 years. About 32.9% and 33.6% had stage II and III cancer, respectively. Significant patients had co-morbidities (15.4%) and complications (13.3%). Fluorouracil (5-FU)-based regimens were given to more than half (56%) of the patients. MRHs were found in 53.1% of the patients, with a mean of 2.45 ± 1.37 MRHs. The most common MRHs were the need for additional drug therapy, sub-therapeutic dose, DDIs, and ADRs. Being on stage IV (AOR = 27.7, 95% CI = 3.85-199.38, p = 0.001), having co-morbidity (AOR = 7.42, 95% CI = 1.80-30.59, p = 0.018) and having complication (AOR = 11.04, 95% CI = 1.72-70.95, p = 0.011) and treated with five or more drugs (AOR = 2.54, 95% CI = 1.07-6.07, p = 0.035) were independent predictors of MRHs.

Conclusion: A fluorouracil-based treatment regimen was most frequently used. MRHs were found in nearly half of CRC patients. Furthermore, MRHs were significantly associated with cancer stage, comorbidity and complication status, and the number of medications used. Because MRHs are common, improving clinical pharmacy services is critical for optimizing drug therapy in CRC patients.

Keywords: colorectal cancer; ethiopia; medication related harm; oncology center; predictors.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Chemotherapy’s used in the treatment of colorectal cancer at UoGCSH.
Figure 2
Figure 2
Severity of drug interactions among colorectal cancer patients at UoGCSH (n = 34).
See this image and copyright information in PMC

References

    1. Douaiher J, Ravipati A, Grams B, et al. Colorectal cancer—global burden, trends, and geographical variations. J Surg Oncol (2017) 115(5):619–30. doi: 10.1002/jso.24578 - DOI - PubMed
    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin (2021) 71(3):209–49. doi: 10.3322/caac.21660 - DOI - PubMed
    1. Peterse EF, Meester RG, Siegel RL, Chen JC, Dwyer A, Ahnen DJ, et al. The impact of the rising colorectal cancer incidence in young adults on the optimal age to start screening: microsimulation analysis I to inform the American Cancer Society colorectal cancer screening guideline. Cancer (2018) 124(14):2964–73. doi: 10.1002/cncr.31543 - DOI - PMC - PubMed
    1. WHO . International Agency Research on Cancer. Latest global cancer data. Available at: https://www.iarc.fr/wp-content/uploads/2018/09/pr263_E.pdf (Accessed January 21, 2023).
    1. Graham A, Adeloye D, Grant L, Theodoratou E, Campbell H. Estimating the incidence of colorectal cancer in Sub–Saharan Africa: A systematic analysis. J Global Health (2012) 2(2). doi: 10.7189/jogh.02.020404 - DOI - PMC - PubMed

LinkOut - more resources